Smith & Nephew SNATS Debt to Equity Ratio 2006-2018 | SNN

Current and historical debt to equity ratio values for Smith & Nephew SNATS (SNN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Smith & Nephew SNATS debt/equity for the three months ending June 30, 2018 was 0.31.
Smith & Nephew SNATS Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-06-30 $1.42B $4.64B 0.31
2017-12-31 $1.42B $4.64B 0.31
2017-06-30 $1.60B $4.20B 0.38
2016-12-31 $1.56B $3.96B 0.40
2015-12-31 $1.43B $3.97B 0.36
2015-06-30 $1.53B $4.05B 0.38
2014-12-31 $1.67B $4.04B 0.41
2014-09-30 $1.94B $4.02B 0.48
2014-06-30 $1.99B $4.16B 0.48
2014-03-31 $0.34B $4.22B 0.08
2013-12-31 $0.35B $4.05B 0.09
2013-09-30 $0.29B $3.91B 0.07
2013-06-30 $0.34B $3.90B 0.09
2013-03-31 $0.21B $3.95B 0.05
2012-12-31 $0.43B $3.88B 0.11
2012-09-30 $0.02B $3.64B 0.00
2012-06-30 $0.02B $3.56B 0.00
2012-03-31 $0.02B $3.45B 0.00
2011-12-31 $0.02B $3.19B 0.01
2011-09-30 $0.02B $3.06B 0.01
2011-06-30 $0.02B $3.13B 0.01
2011-03-31 $0.53B $3.00B 0.18
2010-12-31 $0.64B $2.77B 0.23
2010-09-30 $1.05B $2.48B 0.43
2010-06-30 $1.05B $2.31B 0.45
2010-03-31 $1.01B $2.23B 0.46
2009-12-31 $1.09B $2.18B 0.50
2009-09-30 $1.23B $2.01B 0.61
2009-06-30 $1.27B $1.88B 0.67
2009-03-31 $1.16B $1.71B 0.68
2008-12-31 $1.36B $1.70B 0.80
2008-09-30 $1.39B $1.77B 0.79
2008-06-30 $0.04B $1.81B 0.02
2008-03-31 $0.04B $1.81B 0.02
2007-12-31 $0.04B $1.82B 0.02
2007-09-30 $0.04B $1.91B 0.02
2007-06-30 $0.04B $2.16B 0.02
2007-03-31 $0.02B $2.16B 0.01
2006-12-31 $0.02B $2.17B 0.01
2006-09-30 $0.02B $2.07B 0.01
2006-06-30 $0.02B $2.01B 0.01
2006-03-31 $0.02B $1.89B 0.01
2005-12-31 $0.22B $1.57B 0.14
2005-09-30 $0.19B $1.43B 0.13
2005-06-30 $0.22B $1.44B 0.15
2005-03-31 $0.20B $1.42B 0.14
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.781B $4.765B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $128.261B 19.18
Abbott Laboratories (ABT) United States $126.772B 25.69
Stryker (SYK) United States $64.682B 24.38
Boston Scientific (BSX) United States $51.173B 25.86
Baxter (BAX) United States $35.627B 23.01
Zimmer Biomet Holdings (ZBH) United States $22.919B 14.86
ResMed (RMD) United States $16.435B 31.34
Perrigo (PRGO) Ireland $7.949B 12.06
Bio-Rad Laboratories (BIO) United States $7.499B 47.95
Canopy Growth (CGC) Canada $7.155B 0.00
Hill-Rom Holdings (HRC) United States $6.373B 19.94
Aurora Cannabis (ACB) Canada $5.690B 30.05
Haemonetics (HAE) United States $5.320B 46.79
Insulet (PODD) United States $4.792B 0.00
ICU Medical (ICUI) United States $4.683B 26.09
Hutchison China MediTech (HCM) China $4.520B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.645B 0.00
Neogen (NEOG) United States $3.295B 49.90
Agios Pharmaceuticals (AGIO) United States $3.098B 0.00
NuVasive (NUVA) United States $2.887B 26.87
National Vision Holdings (EYE) United States $2.368B 45.81
Quidel (QDEL) United States $1.995B 26.01
NxStage Medical (NXTM) United States $1.905B 0.00
Phibro Animal Health (PAHC) United States $1.329B 18.81
Aphria (APHA) $1.306B 0.00
AtriCure (ATRC) United States $1.170B 0.00
Cardiovascular Systems (CSII) United States $0.999B 1437.00
VAREX IMAGING (VREX) United States $0.910B 18.23
PetIQ (PETQ) United States $0.848B 21.99
Meridian Bioscience (VIVO) United States $0.771B 24.58
Cerus (CERS) United States $0.769B 0.00
Surmodics (SRDX) United States $0.765B 116.47
OraSure Technologies (OSUR) United States $0.727B 40.93
Lantheus Holdings (LNTH) United States $0.664B 20.56
Omeros (OMER) United States $0.656B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.643B 20.63
MacroGenics (MGNX) United States $0.624B 0.00
NanoString Technologies (NSTG) United States $0.526B 0.00
LeMaitre Vascular (LMAT) United States $0.514B 25.24
Quanterix (QTRX) United States $0.442B 0.00
Owens & Minor (OMI) United States $0.421B 4.76
TG Therapeutics (TGTX) United States $0.414B 0.00
Insys Therapeutics (INSY) United States $0.366B 0.00
Evolus (EOLS) United States $0.336B 0.00
Utah Medical Products (UTMD) United States $0.324B 20.93
VAPOTHERM INC (VAPO) United States $0.301B 0.00
Cytosorbents (CTSO) United States $0.277B 0.00
Surface Oncology (SURF) United States $0.236B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.235B 0.00
Bovie Medical (BVX) United States $0.231B 0.00
BioLife Solutions (BLFS) United States $0.205B 276.75
Rockwell Medical (RMTI) United States $0.172B 0.00
Chimerix (CMRX) United States $0.170B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.139B 0.00
Fonar (FONR) United States $0.135B 6.78
Chembio Diagnostics (CEMI) United States $0.103B 0.00
United-Guardian (UG) United States $0.080B 16.84
Female Health (VERU) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.070B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
Trinity Biotech (TRIB) Ireland $0.063B 17.33
CAS Medical Systems (CASM) United States $0.050B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.046B 0.00
ImmuCell (ICCC) United States $0.040B 0.00
Neurotrope (NTRP) United States $0.035B 0.00
Myomo (MYO) United States $0.023B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.018B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
Akers Biosciences Inc (AKER) United States $0.015B 0.00
Senestech (SNES) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.006B 0.00